Research and clinical trials

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...

Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Guselkumab.

An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did...

A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...

An FDA approval means a new biologic option (guselkumab/Tremfya) is available for adults with moderately to severely active Crohn’s disease and may change prescribing choices. The approval highlights a dosing flexibility...

A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...

A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have...

An FDA approval means a new, approved IL‑23 inhibitor option (guselkumab/TREMFYA) is available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices and offering a fully...

An FDA approval means TREMFYA is now an additional, officially authorized treatment option for adults with moderately to severely active Crohn's disease. The drug offers both IV and SC induction choices and established...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

New treatment studies and biosimilars could affect future options and access to care. The piece also points out growing pediatric Crohn’s care and supports available (like an infusion center).

Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

Cure8 found this source from tmcnet.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.

Based on the title and source metadata, this appears to be a clinical study related to Research and clinical trials. The original article is from knowridge.com.

Based on the title and source metadata, this appears to be a guideline related to Medications. The original article is from msn.com.

This study suggests intestinal ultrasound findings early after diagnosis — especially achieving “transmural remission” within 3 months — may predict better 1-year outcomes (sustained steroid-free remission and less need...

The paper links a Crohn’s disease GWAS signal to reduced LACC1 expression in lymphocytes and to altered immunometabolic function, clarifying a potential mechanism by which genetic variation contributes to IBD risk. It...

Cure8 found this source from precisionmedicineonline.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker. Open the original article for the full...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...

Based on the title and source metadata, this appears to be a clinical study related to Irritable bowel syndrome, Upadacitinib, and JAK inhibitor. The original article is from msn.com.

Dietary patterns may differ between people who develop Crohn’s disease or ulcerative colitis and their healthy relatives; understanding these associations could help guide prevention research and personalized nutrition...

This reports a company moving a MAP-targeted antibiotic-like therapy (RHB-204, related to RHB-104) into a Phase 2 trial for Crohn’s disease with mucosal healing and MAP eradication as key endpoints—topics that could...

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...

Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from mdedge.com.

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from...

This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...

This report describes an investigational drug that appears to reach its intestinal target and produced molecular changes in biopsies from people with fibrostenosing Crohn’s — a form that causes scarring and strictures.

This study points to a possible microbiome biomarker (M. gnavus) tied to joint inflammation in people with Crohn’s disease, which could help explain why some patients develop arthritis and might eventually inform...

The study identifies a specific gut bacterium, Mediterraneibacter gnavus, that may act as a biomarker for joint inflammation in people with Crohn's disease. Understanding microbiome–immune links could eventually help...

AI-assisted capsule endoscopy may improve detection of Crohn’s disease lesions and reduce missed findings, which could affect diagnosis and monitoring. People with IBD may see faster or more consistent reads of capsule...

This study suggests a microbiome‑based biomarker (IgG reactivity to certain gut bacteria, especially M. gnavus) could help identify spondyloarthritis in people with Crohn’s disease and distinguish axial from peripheral...

This project aims to develop wearable-based digital biomarkers to detect IBD flares earlier and make remote monitoring easier, which could help patients and clinicians manage disease more proactively. It describes...

The study points to a specific gut microbe, Mediterraneibacter gnavus, that may be linked to joint inflammation in people with Crohn's disease. If confirmed, a microbial biomarker could help identify who is at risk for...

Cure8 could only read part of this source from news.weill.cornell.edu, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Biomarker, and Joint Inflammation.

If EBV infection raises Crohn's risk, it could point to new causes and therapeutic targets. Many people with or at risk for IBD will want to know whether viral exposure plays a role in their disease or in prevention...

Based on the title and source metadata, this appears to be a clinical trial phase 1 related to Research and clinical trials. The original article is from msn.com.

Adaptive platform trials could speed testing of multiple Crohn’s treatments and make it easier to compare options, which may shorten the time to find effective therapies. The article outlines design choices and...

This study suggests a specific three‑strain probiotic may help some people with Crohn’s disease feel slightly better and absorb certain nutrients better, even though it didn’t reduce core disease activity.

If metabolomic blood markers can reliably indicate IBD risk years before symptoms, researchers may better understand disease development and eventually design earlier detection or prevention strategies. For patients, the...

These are phase 3 results showing subcutaneous guselkumab helped more people reach clinical and endoscopic goals than placebo in moderate-to-severe UC and Crohn’s disease; a fully subcutaneous option could offer more...

If EBV exposure increases the risk of later Crohn's disease, it could help explain one environmental trigger for IBD and point to new research directions for prevention or treatment. Patients may be interested because...

Perianal fistulas are a serious, hard-to-treat complication of Crohn disease. Fast Track status may speed development of a new implantable stem cell therapy that aims to close fistulas and promote local healing. Ongoing...

The article connects psoriasis and Crohn's disease through shared immune pathways and the gut-skin axis, which may matter because people with one condition could have signs or risks related to the other. It emphasizes...